Frequency Therapeutics Inc (NASDAQ:KRRO) — Market Cap & Net Worth
Market Cap & Net Worth: Frequency Therapeutics Inc (KRRO)
Frequency Therapeutics Inc (NASDAQ:KRRO) has a market capitalization of $105.19 Million ($105.19 Million) as of May 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18987 globally and #4184 in its home market, demonstrating a -0.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Frequency Therapeutics Inc's stock price $13.57 by its total outstanding shares 9417295 (9.42 Million). Analyse cash flow conversion of Frequency Therapeutics Inc to see how efficiently the company converts income to cash.
Frequency Therapeutics Inc Market Cap History: 2019 to 2026
Frequency Therapeutics Inc's market capitalization history from 2019 to 2026. Data shows change from $8.25 Billion to $127.79 Million (-44.89% CAGR).
Index Memberships
Frequency Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #541 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1857 of 3165 |
Weight: Frequency Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Frequency Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Frequency Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
157.87x
Frequency Therapeutics Inc's market cap is 157.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $8.25 Billion | $28.95 Million | -$18.75 Million | 285.15x | N/A |
| 2020 | $16.60 Billion | $36.98 Million | -$26.51 Million | 448.92x | N/A |
| 2021 | $2.42 Billion | $14.07 Million | -$84.69 Million | 171.70x | N/A |
| 2024 | $358.52 Million | $2.27 Million | -$83.58 Million | 157.87x | N/A |
Competitor Companies of KRRO by Market Capitalization
Companies near Frequency Therapeutics Inc in the global market cap rankings as of May 5, 2026.
Key companies related to Frequency Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Frequency Therapeutics Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Frequency Therapeutics Inc's market cap moved from $8.25 Billion to $ 127.79 Million, with a yearly change of -44.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $127.79 Million | +69.41% |
| 2025 | $75.43 Million | -78.96% |
| 2024 | $358.52 Million | -20.57% |
| 2023 | $451.37 Million | -75.10% |
| 2022 | $1.81 Billion | -24.95% |
| 2021 | $2.42 Billion | -85.45% |
| 2020 | $16.60 Billion | +101.14% |
| 2019 | $8.25 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Frequency Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $105.19 Million USD |
| MoneyControl | $105.19 Million USD |
| MarketWatch | $105.19 Million USD |
| marketcap.company | $105.19 Million USD |
| Reuters | $105.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Frequency Therapeutics Inc
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oli… Read more